智通财经APP获悉，歌礼制药-B(01672)绩后重挫20%，截至发稿，跌18.38%，报6.84港元，成交额4235.8万港元。
消息面上，歌礼制药发布年度业绩，集团收入人民币128.3万元，同比减少97.73%；股东应占亏损3.01亿元，同比扩大107.95%;每股亏损30.05分。集团的研发费用同比增加39.5%至约3.02亿元人民币。公告称，亏损扩大主要由于肥胖症及其他代谢性疾病的研发开支增加。
据悉，3月12日，歌礼制药发布公告披露，ASC47单药疗法澳大利亚Ib期低密度脂蛋白胆固醇偏高的健康受试者和肥胖症患者中的单次皮下注射研究取得积极顶线结果。此外，该药联合司美格鲁肽的新药临床试验申请获美国食品药品监督管理局（FDA）批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.